HarlanWeismanMD

PubMed

• 119 citations
  Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention
  Keaven M. Anderson, Robert M. Califf, Gregg W. Stone, Franz-Josef Neumann, Gilles Montalescot
  Journal of the American College of Cardiology. 2001-06-15
• 38 citations
  Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.
  Mary Ann Mascelli, Neal S. Kleiman, Stanley J. Marciniak, Lakshmi V. Damaraju, Harlan F. Weisman
  American Heart Journal. 2000-04-01
• PLATELET GLYCOPROTEIN IIB/IIIA ANTAGONISTS IN ISCHEMIC CEREBROVASCULAR DISEASE
  Jacques R. Leclerc, Mary Ann Mascelli, Harlan F. Weisman
  Coronary Artery Disease. 1999-12-01

Journal Articles

• Pharmacodynamic Profile of Short-term Abciximab Treatment Demonstrates Prolonged Platelet Inhibition With Gradual Recovery From GP IIb/IIIa Receptor Blockade.  
  Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE, Circulation
• Increased risk of non Q-wave myocardial infarction after directional atherectomy is platelet-dependent: Evidence from the EPIC trial.  
  Lefkovits J, Blankenship JC, Anderson KM, Stoner GL, Talley JD, Worley SJ, Weisman HF, Califf RM, Topol EJ, J Am Coll Cardiol
• Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during per...  
  Lincoff AM, Tcheng JE, Califf RM, Bass T, Popma J, Teirstein PS, Kleiman NS, Hattel LJ, Anderson HV, Ferguson JJ, Cabot CF, Anderson KM, Berdan LG, Musco MH, Weisman H..., Am J Cardiol
• Randomized placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study.  
  The CAPTURE Investigators, Lancet
• Long-term protection from myocardial ischemic events in a randomized trial of brief integrin 3 blockade with percutaneous coronary intervention.  
  Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, Ivanhoe RJ, Wang AL, Miller DP, Anderson KM and Califf RM, JAMA
• Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization.  
  The EPILOG Investigators, N Engl J Med
• Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab among patients with unstable ang...  
  Lincoff AM, Califf RM, Anderson KM, Weisman HF, Aguirre FV, Kleiman NS, Harrington RA, Topol EJ, J Am Coll Cardiol
• Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty?  
  Khan MM, Ellis SG, Aguirre FV, Weisman HF, Wildermann NM, Califf RM, Topol EJ, Kleiman NS, J Am Coll Cardiol
• Rapid assessment of platelet function using a modified whole blood aggregometer in PTCA patients receiving anti-GPII/IIIa therapy.  
  Mascelli MA, Worley S, Veriabo NJ, Lance E, Mack S, Schaible T, Weisman HF and Jordan R, Circulation
• Abciximab therapy and unplanned coronary stent deployment: Favorable effects on stent utilization, clinical outcomes and bleeding complications.  
  Kereiakes DJ, Lincoff AM, Miller DP, Tcheng JE, Cabot CF, Anderson KM, Weisman HF, Califf RM, Topol EJ, Circulation
• Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: Evidence for a complex interaction in a multicenter trial.  
  Kleiman NS, Lincoff AM, Kereiakes, DJ, Miller DP, Aguirre FV, Anderson K, Weisman HF, Califf RM, Topol EJ, Circulation
• Blockade of the human platelet GPIIb/IIIa receptor by a murine monoclonal antibody Fab fragment (7E3): Potent dose-dependent inhibition of platelet function.  
  Bhattacharya S, Jordan R, Machin S, Senior R, Mackie I, Smith CR, Schaible TF, Weisman HF, Lahiri A, Cardiovasc Drugs Ther
• Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: One year outcome in the EPILOG Trial.  
  Lincoff MA, Tcheng JE, Califf RM, Kereiakes DJ, Kelly TA, Timmis GC, Kleiman NS, Booth JE, Balog C, Cabot CF, Anderson KM, Weisman HF, Topol EJ, Circulation
• Therapeutic heparin concentrations augment platelet reactivity: implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab.  
  Mascelli MA, Kleiman NS, Marciniak SJ Jr, Damaraju L, Weisman HF, Jordan RE, Am Heart J
• Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention.  
  Anderson KM, Califf RM, Stone GW, Neumann FJ, Montalescot G, Miller DP, Ferguson JJ 3rd, Willerson JT, Weisman HF, Topol EJ, J Am Coll Cardiol
• Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa in patients undergoing percutaneous coronary intervention.  
  Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM, Circulation
• A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion.  
  Aversano T, Zhoe W, Nedelman M, Nakada M, Weisman H, J Am Coll Cardiol
• Effect of platelet glycoprotein IIb/IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or direct coronary atherect...  
  Moliterno DJ, Califf RM, Aguirre FV, Anderson K, Sigmon KN, Weisman HF, Topol EJ, Am J Cardiol
• Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty.  
  Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ, Circulation
• Chimeric 7E3 prevents carotid thrombosis in cynomolgus monkeys.  
  Rote WE, Nedelman MA, Mu D-X, Manley PJ, Weisman H, Cunningham MR, Lucchesi BR, Stroke
• Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.  
  The EPIC Investigators, N Engl J Med
• ReoPro Clinical Development: Future Directions and Therapeutic Approaches.  
  Weisman HF, J Invas Cardiol
• Myocardial infarct expansion, infarct extension, and reinfarction: Pathophysiologic concepts.  
  Weisman HF, Healy B, Prog Cardiovasc Dis
• Toward an understanding of the molecular basis of cardiomyopathies.  
  Weisman HF, Weisfeldt ML, J Am Coll Cardiol
• The voltage sensitive calcium channel in the heart.  
  Weisman HF, Heart Failure
• Join now to see all

Books/Book Chapters

• Value in Health Care: Accounting for Cost, Quality, Safety, Outcomes, and Innovation. 
  Chapter: Stakeholder Perspectives on Value: Perspectives from Manufacturers 
  Weisman, Harlan FEditors: Yong PL, Olsen LA, McGinnis JM.National Academies Press, Washington
• The 2009 Pfeiffer Annual Leadership Development. 
  Chapter: Convergence and Innovation 
  Page 179 - 187Weisman, HEditors: David Dotlich, Peter Cairo, Stephen Rhinesmith, and Ron Meeks.Pfeiffer Publishing, San Francisco
• The Learning Healthcare System: Workshop Summary, Institute of Medicine of the National Aademies. 
  Chapter: Broader Post-Marketing Surveillance for Insights on Risk and Effectiveness 
  Weisman, H., Farup, C., Thomas, A., Juhn, P., Buto, KThe National Academies Press, Washington
• Novel Therapeutic Proteins: Selected Case Studies. 
  Chapter: The Evolution of ReoPro® Clinical Development 
  Page 323 - 346Farrell, CF, Barnathan, ES, Weisman HFWiley-VCH
• Handbook of Experimental Pharmacology. 
  Chapter: Current Antiplatelet Therapy 
  Jakubowski, J., Jordan, R.E., Weisman, H.FSpringer-Verlag
• How to Write and Publish in the Medical Sciences. 
  Weisman HFEditors: Edward J. Huth.ISI Press, Philadelphia
• Catheter Ablation of Cardiac Arrhythmias. 
  Chapter: Cellular electrophysiology of electrical discharges 
  Page 37 - 50Levine JH, Spear JF, Kadish AH, Weisman HF, Merillat JC, Moore ENEditors: Melvin M. Scheinman.Martinus Nijhoff Publishing, Boston
• Heart Disease. A textbook of cardiovascular medicine. 
  Chapter: Inhibitors of platelets agreggation: GPIIb/IIIa antagonists 
  Page 1 - 10Coller BS, Anderson KA, Weisman HFEditors: Eugene Braunwald.W.B. Sanders Company
• Adhesion Receptors as Therapeutic Targets. 
  Chapter: Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations 
  Page 281 - 305Jordan RE, Wagner CL, Mascelli MA, Treacy G, Nedelman MA, Woody JN, Weisman HF, Coller BSCRC Press Inc
• Therapeutic Drugs. 
  Chapter: Abciximab Chapter 
  Simoons M, Weisman HF, Jordan RColin Dollery
• Coronary Artery Disease. 
  Chapter: Platelet glycoprotein IIb/IIIa antagonists in ischemic cerebrovascular disease 
  Page 575 - 579LeClerc J, Mascelli MA, Weisman HF
• New Therapeutic Agents in Thrombosis and Thrombolysis. 
  Chapter: The pharmacology and clinical development of abciximab (c7E3 Fab): A monoclonal antibody inhibitor of GPIIb/IIIa and ?v?3 
  Jordan RE, Mascelli MA, Nakada M, Weisman HFMarcel Dekker, Inc, New York
• Molecular Basis of Oxidative Damage by Leukocytes. 
  Chapter: Electron paramagnetic resonance measurements of free radical generation in isolated cells and whole tissues 
  Page 181 - 201Zweier JL, Kuppusamy P, Shandelya SML, Thompson-Gorman S, Weisman HF, Fearon DT, Weisfeldt MLCRC Press Inc
• Join now to see all